RecruitingNCT04731831
Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.
Characterization of Immunogenicity of Tumor Necrosis Factor Inhibitors in Arthritis Patients With Poorer Treatment Response Due to Gender, Obesity and Smoking Status.
Sponsor
Aalborg University Hospital
Enrollment
120 participants
Start Date
Aug 1, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Patients \> 18 years
- Diagnosed with RA, PsA or AS.
- Starting treatment with infliximab or adalimumab.
- Co- treatment with csDMARD or glucocorticoid is acceptable.
- No new bDMARD is initiated at the time of sampling.
Exclusion Criteria1
- \-
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04731831
Related Trials
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT0666333230 locations
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT0717639061 locations
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
NCT007482541 location
Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases
NCT068423161 location
Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study
NCT065284318 locations